Consultants Forum Advertise
Subscribe
Close

  • Free for qualified executives and consultants to industry

  • Receive quarterly issues of Area Development Magazine and special market report and directory issues

Subscribe Now
Renew

Area Development - Site Selection, Facility Planning and Workforce Development

AbbVie Expands North Chicago, Illinois, Production Operations

08/13/2025
American pharmaceutical company AbbVie plans to expand its production operations in North Chicago, Illinois. The $195 million project is expected to create at least 50 jobs.

The investment will include the construction of an active pharmaceutical ingredient facility which will expand the company’s chemical synthesis capabilities supporting domestic production of current and next-generation neuroscience, immunology and oncology medicines. Operations are scheduled to begin in fall 2025.

"Over the next decade, AbbVie will expand production of API, drug products, peptides and medical devices in the U.S. to support future medical breakthroughs," said Robert A. Michael, chairman and chief executive officer, AbbVie. "This is an important step to maintain U.S. leadership in pharmaceutical innovation and deliver next-generation medicines that make a remarkable impact on patients' lives."

The project is being supported by an Economic Development for a Growing Economy (EDGE) agreement with the State.

“This project aligns with the State's vision to attract and retain Illinois companies that are investing in innovation, infrastructure, and workforce development,” noted Illinois Department of Commerce and Economic Opportunity Director Kristin Richards. “We are proud to support businesses like AbbVie that are expanding their operations in Illinois and helping us lead the way in manufacturing.”

AbbVie is a research-based biopharmaceutical company focused on developing and commercializing innovative medicines, known for its work in immunology, oncology, neuroscience, and eye care, among other areas. The company currently operates 11 manufacturing facilities across the U.S.

Exclusive Research